Amgen (AMGN) Stock Forecast & Price Target

Compare

6,738 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

AMGN Analyst Ratings

Moderate Buy

9 Buy

9 Hold

1 Sell

Based on 19 analysts giving stock ratings to

Amgen

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

AMGN Stock 12 Month Forecast

Average Price Target

$333.40

▲(1.06% Upside)

Based on 19 Wall Street analysts offering 12 month price targets for Amgen in the last 3 months. The average price target is $333.40 with a high forecast of $389.00 and a low forecast of $272.00. The average price target represents a 1.06% change from the last price of $329.89.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"251":"$251","390":"$390","285.75":"$285.8","320.5":"$320.5","355.25":"$355.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":389,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$389.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":333.4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$333.40</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":272,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$272.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[251,285.75,320.5,355.25,390],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,337.49,341.4523076923077,345.4146153846154,349.3769230769231,353.33923076923077,357.3015384615385,361.26384615384615,365.22615384615386,369.1884615384615,373.15076923076924,377.1130769230769,381.0753846153846,385.0376923076923,{"y":389,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,337.49,337.17538461538464,336.8607692307692,336.54615384615386,336.23153846153843,335.91692307692307,335.6023076923077,335.2876923076923,334.9730769230769,334.65846153846155,334.34384615384613,334.02923076923076,333.71461538461534,{"y":333.4,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,337.49,332.4523076923077,327.4146153846154,322.3769230769231,317.33923076923077,312.3015384615385,307.26384615384615,302.22615384615386,297.1884615384615,292.15076923076924,287.1130769230769,282.0753846153846,277.0376923076923,{"y":272,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":269.33,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 36, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":252.42,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 28, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":276.42,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":300.76,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":299.65,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":277.05,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":284.12,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 29, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":286.14,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 27, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":292.4,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 30, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":284.89,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 24, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":296.39,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":296.32,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":337.49,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$389.00

Average Price Target$333.40

Lowest Price Target$272.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Hans Engel

Erste Group

―

Buy

―

Upgraded

12/05/25

Amgen upgraded to Buy from Hold at Erste GroupAmgen upgraded to Buy from Hold at Erste Group

Louise Chen

Scotiabank

$385

Buy

16.71%

Upside

Reiterated

12/04/25

Scotiabank Sticks to Its Buy Rating for Amgen (AMGN)

Evan Seigerman

BMO Capital

$335→$372

Buy

12.76%

Upside

Reiterated

12/03/25

Amgen price target raised to $372 from $335 at BMO CapitalAmgen price target raised to $372 from $335 at BMO Capital

Courtney Breen

Bernstein

$335

Buy

1.55%

Upside

Reiterated

11/26/25

Bernstein Remains a Buy on Amgen (AMGN)

Srikripa Devarakonda

Truist Financial

$298→$318

Hold

-3.60%

Downside

Reiterated

11/24/25

Amgen (AMGN) Gets a Hold from Truist Financial

David Amsellem

Piper Sandler

$381

Buy

15.49%

Upside

Reiterated

11/24/25

Analysts' Top Healthcare Picks: Amgen (AMGN), Opus Genetics (IRD)

Unknown Analyst

Mizuho Securities

Not Ranked

Mizuho Securities

$280

Hold

-15.12%

Downside

Reiterated

11/20/25

Amgen (AMGN) Gets a Hold from Mizuho SecuritiesAMGN (N, maintaining PT at $280): Focus remains MariTide, and as we move into 2026, perhaps more attention on olpasiran (as Lp(a) remains an important target for the industry).

Carter Gould

Cantor Fitzgerald

$305→$315

Hold

-4.51%

Downside

Reiterated

11/06/25

Amgen price target raised to $315 from $305 at Cantor FitzgeraldAmgen price target raised to $315 from $305 at Cantor Fitzgerald

Tim Anderson

Bank of America Securities

$272

Sell

-17.55%

Downside

Reiterated

11/05/25

Amgen Stock Overvaluation Concerns Amid Mixed Future Guidance and Pipeline Delays

Mohit Bansal

Wells Fargo

$280→$300

Hold

-9.06%

Downside

Reiterated

11/05/25

Amgen price target raised to $300 from $280 at Wells FargoAmgen price target raised to $300 from $280 at Wells Fargo

Terence Flynn

Morgan Stanley

$333→$329

Hold

-0.27%

Downside

Reiterated

11/05/25

Morgan Stanley Sticks to Its Hold Rating for Amgen (AMGN)

Matt Phipps

William Blair

―

Buy

―

Reiterated

11/05/25

Amgen's Strong Q3 Performance and Promising Pipeline Justify Buy Rating

Luca Issi

RBC Capital

$330

Buy

0.03%

Upside

Reiterated

11/05/25

RBC Capital Reaffirms Their Buy Rating on Amgen (AMGN)

Yaron Werber

TD Cowen

$389

Buy

17.92%

Upside

Reiterated

11/04/25

Amgen's Strong Financial Performance and Strategic Growth Initiatives Justify Buy Rating4:19 AM Amgen (NASDAQ: AMGN) Buy (1) ESG $389.00 Solid Q3 Beats Across The Board–MariTide Ph2 Part 2 In Q4 Is Next Big Catalyst View Full Report THE TD COWEN INSIGHT Q3 revs/EPS beat driven by growth key growth drivers that will more than offset softness of legacy products facing generics (e.g. Prolia/Xgeva/Ravicti). We are bullish on Tezspire and Uplizna label expansions, and KOLs are confident in MariTide's prospects. MTSR's bidding highlights value of long-acting obesity drugs and Ph2 Part2 data in Q4 will clarify MariTide's oppy as maintenance.

Jay Olson

Oppenheimer

$380

Buy

15.19%

Upside

Reiterated

10/24/25

Oppenheimer Sticks to Their Buy Rating for Amgen (AMGN)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Hans Engel

Erste Group

―

Buy

―

Upgraded

12/05/25

Amgen upgraded to Buy from Hold at Erste GroupAmgen upgraded to Buy from Hold at Erste Group

Louise Chen

Scotiabank

$385

Buy

16.71%

Upside

Reiterated

12/04/25

Scotiabank Sticks to Its Buy Rating for Amgen (AMGN)

Evan Seigerman

BMO Capital

$335→$372

Buy

12.76%

Upside

Reiterated

12/03/25

Amgen price target raised to $372 from $335 at BMO CapitalAmgen price target raised to $372 from $335 at BMO Capital

Courtney Breen

Bernstein

$335

Buy

1.55%

Upside

Reiterated

11/26/25

Bernstein Remains a Buy on Amgen (AMGN)

Srikripa Devarakonda

Truist Financial

$298→$318

Hold

-3.60%

Downside

Reiterated

11/24/25

Amgen (AMGN) Gets a Hold from Truist Financial

David Amsellem

Piper Sandler

$381

Buy

15.49%

Upside

Reiterated

11/24/25

Analysts' Top Healthcare Picks: Amgen (AMGN), Opus Genetics (IRD)

Unknown Analyst

Mizuho Securities

Not Ranked

Mizuho Securities

$280

Hold

-15.12%

Downside

Reiterated

11/20/25

Carter Gould

Cantor Fitzgerald

$305→$315

Hold

-4.51%

Downside

Reiterated

11/06/25

Amgen price target raised to $315 from $305 at Cantor FitzgeraldAmgen price target raised to $315 from $305 at Cantor Fitzgerald

Tim Anderson

Bank of America Securities

$272

Sell

-17.55%

Downside

Reiterated

11/05/25

Amgen Stock Overvaluation Concerns Amid Mixed Future Guidance and Pipeline Delays

Mohit Bansal

Wells Fargo

$280→$300

Hold

-9.06%

Downside

Reiterated

11/05/25

Amgen price target raised to $300 from $280 at Wells FargoAmgen price target raised to $300 from $280 at Wells Fargo

Terence Flynn

Morgan Stanley

$333→$329

Hold

-0.27%

Downside

Reiterated

11/05/25

Morgan Stanley Sticks to Its Hold Rating for Amgen (AMGN)

Matt Phipps

William Blair

―

Buy

―

Reiterated

11/05/25

Amgen's Strong Q3 Performance and Promising Pipeline Justify Buy Rating

Luca Issi

RBC Capital

$330

Buy

0.03%

Upside

Reiterated

11/05/25

RBC Capital Reaffirms Their Buy Rating on Amgen (AMGN)

Yaron Werber

TD Cowen

$389

Buy

17.92%

Upside

Reiterated

11/04/25

Jay Olson

Oppenheimer

$380

Buy

15.19%

Upside

Reiterated

10/24/25

Oppenheimer Sticks to Their Buy Rating for Amgen (AMGN)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Amgen

1 Month

xxx

Success Rate

23/42 ratings generated profit

Average Return

+1.08%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 54.76% of your transactions generating a profit, with an average return of +1.08% per trade.

3 Months

xxx

Success Rate

27/42 ratings generated profit

Average Return

+4.94%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 64.29% of your transactions generating a profit, with an average return of +4.94% per trade.

1 Year

Yaron WerberTD Cowen

Success Rate

33/42 ratings generated profit

Average Return

+14.14%

reiterated a buy rating last month

Copying Yaron Werber's trades and holding each position for 1 Year would result in 78.57% of your transactions generating a profit, with an average return of +14.14% per trade.

2 Years

xxx

Success Rate

31/32 ratings generated profit

Average Return

+17.14%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 96.88% of your transactions generating a profit, with an average return of +17.14% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

AMGN Analyst Recommendation Trends

Rating

Aug 25

Sep 25

Oct 25

Nov 25

Dec 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, AMGN has received 25 Buy Ratings, 12 Hold Ratings, and 1 Sell Ratings. AMGN average Analyst price target in the past 3 months is 333.40.

Each month's total comprises the sum of three months' worth of ratings.

AMGN Financial Forecast

AMGN Earnings Forecast

Next quarter’s earnings estimate for AMGN is $4.72 with a range of $4.05 to $5.74. The previous quarter’s EPS was $5.64. AMGN beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year AMGN has Performed in-line its overall industry.

AMGN Sales Forecast

Next quarter’s sales forecast for AMGN is $9.46B with a range of $8.98B to $9.87B. The previous quarter’s sales results were $9.59B. AMGN beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year AMGN has Performed in-line its overall industry.

AMGN Stock Forecast FAQ

What is AMGN’s average 12-month price target, according to analysts?

Based on analyst ratings, Amgen’s 12-month average price target is 333.40.

What is AMGN’s upside potential, based on the analysts’ average price target?

Amgen has 1.06% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is AMGN a Buy, Sell or Hold?

Amgen has a consensus rating of Moderate Buy which is based on 9 buy ratings, 9 hold ratings and 1 sell ratings.

What is Amgen’s price target?

The average price target for Amgen is 333.40. This is based on 19 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $389.00 ,the lowest forecast is $272.00. The average price target represents 1.06% Increase from the current price of $329.89.

What do analysts say about Amgen?

Amgen’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 19 Wall Streets Analysts.

How can I buy shares of AMGN?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Amgen (AMGN) Stock Forecast & Price Target

AMGN Analyst Ratings

AMGN Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Amgen

AMGN Analyst Recommendation Trends

AMGN Financial Forecast

AMGN Earnings Forecast

AMGN Sales Forecast

AMGN Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts